Car allowance (Car Data decides by location) up to $1,100.00 (no gas card or mileage).
IC uncapped and the target is $62k.
Recruiter wouldn't divulge the base pay range.
No sign on bonus.
2,500 RSUs (strike price on DOH) with a four-year vesting schedule.
Offers in late May depending on FDA review and acceptance of the first IgA / NDA submission.
ESPP is at a 15% discount with a six month enrollment.
Adding 55 reps for a total of 72 in Nephrology.
Training dates are 6/13/22 and 6/27/22.
NSM and launch on 7/25/22 in San Diego, CA.
Interview process is three interviews (1 - hiring manager, 2 (panel) hiring manager, head of sales, and HR, 3 pending).
There isn't a backup plan if the first drug indication (IgA) isn't approved this year. They are counting on the second indication/approval (FSGS) to keep everyone afloat if the first indication / approval is delayed or not approved.
The scary part is the unknown acceptance of the NDA. Also, the company expects BOTH indications to be block blusters in a Rare Disease space. Many of the current reps feel that the company is hiring too many reps for a rare disease indication.
